The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for ...
The company's latest launch in this field, Alyftrek, can be taken once daily -- versus twice a day for the one before that.
- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one ...
Add Yahoo as a preferred source to see more of our stories on Google. Positive Trikafta results set a benchmark of efficacy for future CF therapies. Photo by filadendron/E+ via Getty Images. On 18 May ...
Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not ...
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...
Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX ...
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its ...
Yesterday, the FDA approved the use of Trikafta, a triple combination therapy, for treatment of the most common cystic fibrosis (CF) mutation. This is the first medication to be approved for use among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results